These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15356820)

  • 21. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.
    Antinori A; Perno CF; Giancola ML; Forbici F; Ippolito G; Hoetelmans RM; Piscitelli SC
    Clin Infect Dis; 2005 Dec; 41(12):1787-93. PubMed ID: 16288405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
    Negredo E; Paredes R; Peraire J; Pedrol E; Côté H; Gel S; Fumoz CR; Ruiz L; Abril V; Rodriguez de Castro E; Ochoa C; Martinez-Picado J; Montaner J; Rey-Joly C; Clotet B;
    Antivir Ther; 2004 Dec; 9(6):889-93. PubMed ID: 15651747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.
    Monpoux F; Sirvent N; Cottalorda J; Mariani R; Lefbvre JC
    AIDS; 1997 Oct; 11(12):1523-5. PubMed ID: 9342078
    [No Abstract]   [Full Text] [Related]  

  • 29. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
    Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
    J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
    Descamps D; Flandre P; Joly V; Meiffrédy V; Peytavin G; Izopet J; Tamalet C; Zeng AF; Harel M; Lastère S; Aboulker JP; Yéni P; Brun-Vézinet F;
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):464-71. PubMed ID: 12473833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
    Sukasem C; Churdboonchart V; Chasombat S; Kohreanudom S; Watitpun C; Pasomsub E; Piroj W; Tiensuwan M; Chantratita W
    Infection; 2007 Apr; 35(2):81-8. PubMed ID: 17401711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
    von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
    Quirino T; Niero F; Ricci E; Pusterla L; Carradori S; Gabbuti A; Iemoli E; Landonio S; Faggion I; Bonfanti P;
    Antivir Ther; 2000 Sep; 5(3):195-7. PubMed ID: 11075939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.
    Pillay D; Walker AS; Gibb DM; de Rossi A; Kaye S; Ait-Khaled M; Muñoz-Fernandez M; Babiker A
    J Infect Dis; 2002 Sep; 186(5):617-25. PubMed ID: 12195348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spring cleaning in trial land.
    Gilden D
    GMHC Treat Issues; 1997 Mar; 11(3):4-7. PubMed ID: 11364275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
    Havlir DV; Hellmann NS; Petropoulos CJ; Whitcomb JM; Collier AC; Hirsch MS; Tebas P; Sommadossi JP; Richman DD
    JAMA; 2000 Jan; 283(2):229-34. PubMed ID: 10634339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ACTG 320 trial halted as three-drug arm proves superior.
    AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.